🇺🇸 Buprenorphine transdermal patches in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 13

Most-reported reactions

1. Product Adhesion Issue — 4 reports (30.77%)
2. Pain — 3 reports (23.08%)
3. Application Site Pain — 1 report (7.69%)
4. Application Site Rash — 1 report (7.69%)
5. Drug Ineffective — 1 report (7.69%)
6. Hypersensitivity — 1 report (7.69%)
7. Product Substitution Issue — 1 report (7.69%)
8. Pruritus — 1 report (7.69%)

Source database →

Frequently asked questions

Is Buprenorphine transdermal patches approved in United States?

Buprenorphine transdermal patches does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Buprenorphine transdermal patches in United States?

Mundipharma (China) Pharmaceutical Co. Ltd is the originator. The local marketing authorisation holder may differ — check the official source linked above.